WO2011083998A3 - 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 - Google Patents

바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 Download PDF

Info

Publication number
WO2011083998A3
WO2011083998A3 PCT/KR2011/000097 KR2011000097W WO2011083998A3 WO 2011083998 A3 WO2011083998 A3 WO 2011083998A3 KR 2011000097 W KR2011000097 W KR 2011000097W WO 2011083998 A3 WO2011083998 A3 WO 2011083998A3
Authority
WO
WIPO (PCT)
Prior art keywords
biguanide derivative
preparation
pharmaceutical composition
active ingredient
composition containing
Prior art date
Application number
PCT/KR2011/000097
Other languages
English (en)
French (fr)
Other versions
WO2011083998A2 (ko
Inventor
김성욱
전성수
민창희
김영웅
강민석
오병규
박세환
김용은
김덕
이지선
오주훈
Original Assignee
한올바이오파마주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한올바이오파마주식회사 filed Critical 한올바이오파마주식회사
Priority to JP2012547967A priority Critical patent/JP2013516461A/ja
Priority to US13/520,902 priority patent/US9416098B2/en
Priority to EP11731936.8A priority patent/EP2522653A4/en
Priority to CN2011800056035A priority patent/CN102725263A/zh
Publication of WO2011083998A2 publication Critical patent/WO2011083998A2/ko
Publication of WO2011083998A3 publication Critical patent/WO2011083998A3/ko
Priority to US15/206,780 priority patent/US9993446B2/en
Priority to US15/976,613 priority patent/US10376480B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/02—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of guanidine from cyanamide, calcium cyanamide or dicyandiamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/04—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of guanidine from ammonium thiocyanate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/06—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

본 발명은 N1-N5-치환된 화학식 1로 표시되는 바이구아나이드 유도체 또는 그의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 약학 조성물을 제공한다. 본 발명의 바이구아나이드 유도체는 기존 약물에 비해 적은 양으로도 우수한 AMPKα 활성화 효과 및 암세포 증식 억제 효과를 나타내어 당뇨, 비만, 고지혈증, 고콜레스테롤혈증, 지방간, 관상동맥질환, 골다공증, 다낭성 난소증후군, 대사성 증후군, 암 등의 치료를 위해 유용하게 이용될 수 있다.
PCT/KR2011/000097 2010-01-06 2011-01-06 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 WO2011083998A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2012547967A JP2013516461A (ja) 2010-01-06 2011-01-06 ビグアニド誘導体、その製造方法及びこれを有効成分として含有する薬学組成物
US13/520,902 US9416098B2 (en) 2010-01-06 2011-01-06 Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
EP11731936.8A EP2522653A4 (en) 2010-01-06 2011-01-06 BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
CN2011800056035A CN102725263A (zh) 2010-01-06 2011-01-06 双胍衍生物、其制备方法以及包含所述双胍衍生物作为活性成分的药物组合物
US15/206,780 US9993446B2 (en) 2010-01-06 2016-07-11 Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient
US15/976,613 US10376480B2 (en) 2010-01-06 2018-05-10 Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0001021 2010-01-06
KR20100001021 2010-01-06
KR10-2011-0001438 2011-01-06
KR1020110001438A KR101274981B1 (ko) 2010-01-06 2011-01-06 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/520,902 A-371-Of-International US9416098B2 (en) 2010-01-06 2011-01-06 Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
US15/206,780 Division US9993446B2 (en) 2010-01-06 2016-07-11 Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

Publications (2)

Publication Number Publication Date
WO2011083998A2 WO2011083998A2 (ko) 2011-07-14
WO2011083998A3 true WO2011083998A3 (ko) 2011-10-27

Family

ID=44919837

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2011/000098 WO2011083999A2 (ko) 2010-01-06 2011-01-06 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
PCT/KR2011/000097 WO2011083998A2 (ko) 2010-01-06 2011-01-06 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000098 WO2011083999A2 (ko) 2010-01-06 2011-01-06 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물

Country Status (6)

Country Link
US (5) US9133110B2 (ko)
EP (2) EP2522653A4 (ko)
JP (1) JP2013516461A (ko)
KR (4) KR101285719B1 (ko)
CN (2) CN102725263A (ko)
WO (2) WO2011083999A2 (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725263A (zh) 2010-01-06 2012-10-10 韩诺生物制药株式会社 双胍衍生物、其制备方法以及包含所述双胍衍生物作为活性成分的药物组合物
EP2742019B1 (en) * 2011-08-08 2021-03-03 Immunomet Therapeutics Inc. N1-cyclic amine-n5-substituted phenyl biguanide derivatives and pharmaceutical composition comprising the same
WO2013022279A2 (en) 2011-08-08 2013-02-14 Hanall Biopharma Co., Ltd. N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
WO2013188452A1 (en) * 2012-06-11 2013-12-19 The Regents Of The University Of California Compounds and methods of treating cancer
EP2874997A4 (en) 2012-07-19 2016-01-06 Univ Drexel NEW SIGMA RECEPTOR LIGANDS AND METHOD FOR REGULATING CELLULAR PROTEIN HOMEOSTASIS THEREWITH
KR102034899B1 (ko) * 2013-02-07 2019-10-22 이뮤노메트테라퓨틱스 인코포레이티드 Ν１-고리아민-ν５-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
WO2014123364A1 (en) * 2013-02-07 2014-08-14 Hanall Biopharma Co., Ltd. N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
KR101642587B1 (ko) 2013-08-23 2016-07-25 가톨릭대학교 산학협력단 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물
WO2015026215A1 (ko) * 2013-08-23 2015-02-26 가톨릭대학교 산학협력단 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물
US10272055B2 (en) * 2014-03-06 2019-04-30 Regents Of The University Of Minnesota Therapeutic compounds and methods
CN111848494B (zh) * 2014-04-17 2023-08-01 伊谬诺米特医疗有限公司 胍化合物及其用途
US20160120876A1 (en) * 2014-04-28 2016-05-05 Chi-Ying Huang Pharmaceutical composition for treatment of cancer using phenothiazine
CN111407753A (zh) * 2014-04-29 2020-07-14 韩国加图立大学校产学协力团 具有免疫疾病治疗效果的新型化合物及其应用
WO2015167243A1 (ko) * 2014-04-29 2015-11-05 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
CN104262205B (zh) * 2014-09-02 2017-04-12 浙江工业大学 N‑芳基双胍氢碘酸盐类化合物及其制备方法和应用
CN104230760B (zh) * 2014-09-02 2016-07-06 浙江工业大学 N-芳基取代的双胍氢溴酸盐类化合物及制备方法和应用
KR102216701B1 (ko) 2014-11-20 2021-02-18 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 화합물 및 이의 용도
CZ307146B6 (cs) * 2015-03-31 2018-02-07 Kkcg Se Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva
US10215554B2 (en) * 2015-04-17 2019-02-26 Industry-University Cooperation Foundation Hanyang University Apparatus and method for non-contact sample analyzing using terahertz wave
WO2016175357A1 (en) * 2015-04-30 2016-11-03 Immunomet Therapeutics Inc. Guanidine compounds and use thereof
CN104961656B (zh) * 2015-05-27 2017-01-25 山西大学 一种双胍化合物及其制备方法
CN104829497B (zh) * 2015-06-01 2017-07-18 上海仁力医药科技有限公司 一种双胍类化合物及其制备方法和应用
CN104829496B (zh) * 2015-06-01 2017-03-15 高尔医药科技(上海)有限公司 双胍类化合物及其制备方法与应用
CN104926695B (zh) * 2015-06-01 2017-05-31 上海仁力医药科技有限公司 防治辐射损伤的化合物rl‑66301、单晶及其制备方法和应用
KR101949451B1 (ko) 2015-10-13 2019-05-10 주식회사 이노파마스크린 염증성 장 질환 및 아토피 피부염 치료용 조성물
KR101796479B1 (ko) 2016-06-24 2017-11-13 주식회사 인코스팜 피부 염증 또는 노화를 개선하는 신규 자가포식작용 활성화 유도 화합물
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11261157B2 (en) 2016-12-08 2022-03-01 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
CN106986791A (zh) * 2017-05-11 2017-07-28 杜剑平 一种治疗肿瘤的药物化合物及其制备方法和应用
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases
CN108030777B (zh) * 2017-12-05 2019-11-12 湖南师范大学 氯胍在制备抗肿瘤药物中的应用
EP3802522A1 (en) 2018-06-05 2021-04-14 Institut Curie Compounds with biguanidyl radical and uses thereof
CN108785106B (zh) * 2018-06-05 2021-03-16 中国科学院上海硅酸盐研究所 一种胶状含银磷酸钙纳米复合材料及其制备方法和应用
CN111018748A (zh) * 2019-12-27 2020-04-17 广东省生物医药技术研究所 化合物(s)-1-(1-萘基)乙基双胍及其制备方法和应用
US11091426B1 (en) 2020-05-05 2021-08-17 United Arab Emirates University Cycloheptylamine derivatives as anti-diabetic agents
WO2022106505A1 (en) 2020-11-18 2022-05-27 Institut Curie Dimers of biguanidines and their therapeutic uses
US20240067603A1 (en) * 2020-12-16 2024-02-29 Regents Of The University Of Minnesota Cubanyl biguanide compounds
CN113354561B (zh) * 2021-04-17 2023-03-28 中山大学 双胍衍生物及其应用与制剂
CN114605291B (zh) * 2022-04-10 2023-11-14 烟台大学 蒽甲基-双胍类抗癌化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960949A (en) * 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
WO2001091696A2 (fr) * 2000-05-26 2001-12-06 Centre National De La Recherche Scientifique (Cnrs) Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
WO2009113092A2 (en) * 2008-01-23 2009-09-17 Usv Limited Process for preparation of proguanil hydrochloride

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB607720A (en) 1945-12-31 1948-09-03 Arthur Donald Ainley Manufacture of biguanide derivatives
DE833959C (de) * 1946-01-25 1952-03-13 Ici Ltd Verfahren zur Herstellung von chemotherapeutisch wertvollen Biguanidderivaten
US2531404A (en) * 1948-02-25 1950-11-28 Ici Ltd Biguanide compounds
US2631146A (en) * 1952-11-13 1953-03-10 American Cyanamid Co Biguanide salts of penicillin
US2768204A (en) * 1956-02-27 1956-10-23 American Cyanamid Co Guanylchloroformamidine hydrochlorides
DE1291331B (de) * 1964-10-16 1969-03-27 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von Biguanidsalzen aus Guanidinen
US3366650A (en) * 1965-10-07 1968-01-30 Squibb & Sons Inc Tetra-and penta-fluoro-phenyl- and phenylalkyl-biguanides and salts thereof
JPS5283906A (en) * 1976-01-01 1977-07-13 Hoffmann La Roche Biguanide salt
US4183958A (en) * 1978-09-26 1980-01-15 Gaf Corporation Fungicidal 1-(alkoxyphenyl)-5-(substituted phenyl) biguanide compounds
CA2064664C (en) * 1991-04-05 2000-01-11 Hiroshi Ishikawa Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives
JP2662343B2 (ja) * 1991-06-19 1997-10-08 大塚製薬株式会社 モノビグアナイド誘導体とこの誘導体を含有した消毒薬
ES2529180T3 (es) 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
KR100774774B1 (ko) * 2006-07-20 2007-11-07 일동제약주식회사 메트포르민 서방성 제제 및 그 제조방법
US8058312B2 (en) * 2007-01-29 2011-11-15 Hanall Biopharma Co., Ltd. N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
KR20090005513A (ko) * 2007-07-09 2009-01-14 한올제약주식회사 메트포르민 말론산염, 그의 제조 방법 및 그를 포함하는약제학적 조성물
US8835506B2 (en) * 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
KR101041428B1 (ko) * 2008-10-13 2011-06-14 한국화학연구원 Ｎ1-2-티오펜-2-일에틸-ｎ2-치환된 바이구아나이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
KR101083300B1 (ko) * 2008-10-13 2011-11-14 한국화학연구원 Ｎ1-벤조［1,3］다이옥솔-5-일메틸-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
CN102725263A (zh) 2010-01-06 2012-10-10 韩诺生物制药株式会社 双胍衍生物、其制备方法以及包含所述双胍衍生物作为活性成分的药物组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960949A (en) * 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
WO2001091696A2 (fr) * 2000-05-26 2001-12-06 Centre National De La Recherche Scientifique (Cnrs) Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
WO2009113092A2 (en) * 2008-01-23 2009-09-17 Usv Limited Process for preparation of proguanil hydrochloride

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARRINGTON, H.C. ET AL.: "Synthetic Antimalarials, Part XLIX. The Structure and Synthesis of the Dihydrotriazine Metabolite of Proguanil", JOURNAL OF CHEM. SOC., 1954, 1 January 1954 (1954-01-01), pages 1017 - 1031 *
See also references of EP2522653A4 *
SHAW, JOHN T. ET AL.: "The preparation of Certain Amino-Substituted Perfluoroalkyl-s- Triazines", J. ORG. CHEM., vol. 24, 30 November 1959 (1959-11-30), pages 1809 - 1811 *

Also Published As

Publication number Publication date
WO2011083999A3 (ko) 2011-11-17
US20120283299A1 (en) 2012-11-08
US10376480B2 (en) 2019-08-13
EP2522654A2 (en) 2012-11-14
US9416098B2 (en) 2016-08-16
JP2013516461A (ja) 2013-05-13
CN102725264B (zh) 2014-12-17
KR20110081093A (ko) 2011-07-13
WO2011083999A2 (ko) 2011-07-14
KR101274981B1 (ko) 2013-06-18
EP2522653A2 (en) 2012-11-14
CN102725264A (zh) 2012-10-10
US9133110B2 (en) 2015-09-15
KR101715984B1 (ko) 2017-03-14
KR101285719B1 (ko) 2013-07-18
KR20110081095A (ko) 2011-07-13
US20160317478A1 (en) 2016-11-03
US9993446B2 (en) 2018-06-12
US20150376123A1 (en) 2015-12-31
WO2011083998A2 (ko) 2011-07-14
US20120309799A1 (en) 2012-12-06
KR20130069704A (ko) 2013-06-26
EP2522653A4 (en) 2013-06-12
US9464042B2 (en) 2016-10-11
KR20130060250A (ko) 2013-06-07
KR101704683B1 (ko) 2017-02-09
US20180256520A1 (en) 2018-09-13
CN102725263A (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
WO2011083998A3 (ko) 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
EP4071149A3 (en) Heterocyclic compounds and uses thereof
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2009149139A8 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2013022278A3 (en) N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
MX2011012122A (es) Derivados de tiofeno.
WO2008142859A1 (ja) 新規なスピロオキシインドール化合物及びこれを含有する医薬
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2012010977A3 (en) Single daily dosage form for prevention and treatment of metabolic syndrome
WO2008119685A3 (en) Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2011085643A8 (zh) 吡啶并环衍生物
WO2013022279A3 (en) N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
WO2010150144A3 (en) Low dose pharmaceutical compositions of celecoxib

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180005603.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11731936

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012547967

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13520902

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1904/MUMNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011731936

Country of ref document: EP